share_log

Chardan Capital Reiterates Buy on Adverum Biotechnologies, Maintains $4 Price Target

Benzinga ·  Mar 19 08:54

Chardan Capital analyst Daniil Gataulin reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment